37results about How to "Effective inhibitor" patented technology

Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.

The present invention relates to novel compounds, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably a galectin-3.

A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine / threonine and tyrosine kinases and a serine / threonine and tyrosine kinases modulating agent. Novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents, production method thereof and uses thereof. In particular, new derivatives of tetrahalogenated benzimidazole with serine / threonine and tyrosine kinases inhibitory properties, preferably selected from the group of PIM, HIPK, DYRK, CLK, CDK, FLT, PKG, Haspin, MER, TAO, MNK, TRK kinases which exhibit superior pharmacological actions, and can be useful for the treatment of disease conditions, especially cancers depending on serine / threonine and tyrosine kinases, such as but not limited to leukemias and solid tumors.

There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A / B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and / or mTOR) is desired and / or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.

A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine / threonine and tyrosine kinases and a serine / threonine and tyrosine kinases modulating agent. Novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents, production method thereof and uses thereof. In particular, new derivatives of tetrahalogenated benzimidazole with serine / threonine and tyrosine kinases inhibitory properties, preferably selected from the group of PIM, HIPK, DYRK, CLK, CDK, FLT, PKG, Haspin, MER, TAO, MNK, TRK kinases which exhibit superior pharmacological actions, and can be useful for the treatment of disease conditions, especially cancers depending on serine / threonine and tyrosine kinases, such as but not limited to leukemias and solid tumors.

The present invention provides methods for identifying candidate compounds for limiting development of and / or treating diabetes, and methods for limiting development of and / or treating diabetes.

A nutritional supplement composition contains inhibitors of alpha-glucosidase and alpha-amylase substantially in the absence of lipase inhibitors. The composition can include touchi extract and phaseolamin as the alpha-glucosidase and alpha-amylase inhibitor, respectively. A method of limiting the absorption of carbohydrates contained in a foodstuff includes administering the nutritional supplement composition prior to consumption of the carbohydrates, and a method of promoting weight loss in an individual includes administering the nutritional supplement composition to the individual over a period of days.